The Fibrolamellar Cancer Foundation (FCF) is honored to receive an additional third year of funding from the Chan Zuckerberg Initiative (CZI) to support the expansion of its research network and accelerate its work to find a cure for fibrolamellar carcinoma (FLC). “We are extremely grateful for the opportunities that this additional grant provides,” said John Hopper, President of FCF. “By continuing to invest in our activities, CZI is confirming their belief in our organization and mission.”
Two years ago, FCF was selected as one of the first 30 rare disease organizations to be part of CZI’s Rare As One (RAO) Network. Twenty additional organizations were selected in November 2021, bringing the current RAO cohort up to fifty grantees. The CZI funding is meant to strengthen the organizational capacity of rare disease organizations, support the development of international patient-led collaborative research networks, and align patients and researchers towards shared priorities.
Over the past two years, CZI’s Rare As One Project has provided invaluable training, mentorship and capacity-building services to FCF. It has accelerate the growth of FCF’s research network, supported the launch of our webinar series and facilitated gatherings among scientists, clinicians, patients, and caregivers. Most critically, however, it has enabled the organization to learn from and directly collaborate with many other rare disease foundations. “We look forward to our continued involvement with the RAO community as we strive to find a cure for fibrolamellar,” John Hopper noted.
For more information on the Rare As One Project and the Chan Zuckerberg Initiative click here.